OBJECTIVE: The purpose of this study was to estimate the direct cost of diagnosing and treating melanoma disease in Sao Paulo (Brazil) between the years 2000 and 2007. METHODS: The project Clinical Practice Guidelines in Oncology was used, adapted to the proceedings of SOBECCan Foundation. The estimated costs were based on the values of the medical treatment paid by the Brazilian National Health System (SUS) and private healthcare insurance companies (PHIC) in 2007. RESULTS: The total cost was estimated in R$33,012,725.1 (SUS) and R$76,133,662.8 (PHIC). Stages 0, I and II comprised about 4.2% (SUS) and 1.3% (PHIC) of the total cost; stages III and IV amounted to 95.8% and 98.7% of the total cost, respectively. CONCLUSION: The diagnosis of malignant melanoma in its initial stages reduces treatment costs generating considerable savings of resources for both National Health System and private healthcare insurance companies.
OBJECTIVE: The purpose of this study was to estimate the direct cost of diagnosing and treating melanoma disease in Sao Paulo (Brazil) between the years 2000 and 2007. METHODS: The project Clinical Practice Guidelines in Oncology was used, adapted to the proceedings of SOBECCan Foundation. The estimated costs were based on the values of the medical treatment paid by the Brazilian National Health System (SUS) and private healthcare insurance companies (PHIC) in 2007. RESULTS: The total cost was estimated in R$33,012,725.1 (SUS) and R$76,133,662.8 (PHIC). Stages 0, I and II comprised about 4.2% (SUS) and 1.3% (PHIC) of the total cost; stages III and IV amounted to 95.8% and 98.7% of the total cost, respectively. CONCLUSION: The diagnosis of malignant melanoma in its initial stages reduces treatment costs generating considerable savings of resources for both National Health System and private healthcare insurance companies.
Authors: Raquel Bissacotti Steglich; Silvana Cardoso; Maria Helena da Costa Naumann Gaertner; Karina Munhoz de Paula Alves Coelho; Tania Ferreira Cestari; Selma Cristina Franco Journal: An Bras Dermatol Date: 2018 Jul-Aug Impact factor: 1.896
Authors: Vanessa Milani; Ana Laura de Sene Amâncio Zara; Everton Nunes da Silva; Larissa Barbosa Cardoso; Maria Paula Curado; Rejane Faria Ribeiro-Rotta Journal: PLoS One Date: 2021-02-17 Impact factor: 3.240
Authors: Alessandro G Campolina; Tania Y Yuba; Tassia C Decimoni; Roseli Leandro; Maria Del Pilar Estevez Diz; Hillegonda M D Novaes; Patrícia C de Soárez Journal: Front Public Health Date: 2018-07-27